Actuate Therapeutics closed at $0.37 on Nov 4, up 5.69%, 95.2% below its 52-week closing high. Volume of 303.7K shares was 0.55× its 20-day average (below normal).
Split-adjusted performance: -54.4% over one month, -87.6% over six months, -94.5% over one year.
Short interest was 1.9M shares at the Oct 15 settlement, up 40.4% from the prior report (19.2% of float, 4.7 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| ACTUActuate Therapeutics | $0.3699 | +5.69% | −87.6% | — | — | — | $8.9M | |
| MTVAMetaVia | $1.34 | +6.35% | −4.3% | — | — | — | $8.8M | Compare |
| LTRNLantern Pharma | $0.5866 | −2.61% | −72.6% | — | — | — | $8.8M | Compare |
| GTBPGT Biopharma | $4.84 | −8.16% | −51.9% | — | — | — | $8.7M | Compare |
| TOVXTheriva Biologics | $0.1900 | +4.40% | −50.3% | — | — | — | $8.7M | Compare |
| CURXCuranex Pharmaceuticals | $5.80 | −6.30% | −17.7% | — | — | — | $9.1M | Compare |
| MBRXMoleculin Biotech | $8.46 | +1.93% | −82.9% | — | — | — | $8.6M | Compare |
| CALCCalciMedica | $1.35 | −8.50% | −56.8% | — | — | — | $9.2M | Compare |
| LEXXLexaria Bioscience | $4.07 | +0.99% | −59.8% | −100.0% | — | — | $8.6M | Compare |
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
